+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region (Europe, APAC), And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 145 Pages
  • July 2024
  • Region: Global
  • Grand View Research
  • ID: 5415449
Description Jump to:
The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030, growing at a CAGR of 9.68% from 2024 to 2030, according to a new report. The market is expected to show lucrative growth due to rising outsourcing trends and increasing R&D expenditure.

Healthcare contract development and manufacturing organization (CDMO) provide outsourcing services to various pharmaceutical industries on a contract basis. An increase in outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing requirement among pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on research and development activities for medical device contract development and manufacturing. Over the past 10 years, several pharmaceutical companies have turned to CMOs, CROs, and CDMOs to assist in pre-formulation and development & manufacturing of their novel innovations. Outsourcing is a high growth market, and most spending is focused on early development.

Around 75% of new drug pipelines come from small- and midsized biopharmaceutical companies. These companies have high profit margins, which make them easy targets for healthcare providers who are trying to reduce costs. Thus, instead of investing in establishing their own infrastructure, it is profitable for these companies to outsource services to third-party organizations that have expertise and the required equipment. Several pharmaceutical companies are seeking outsourced services for optimizing the development of their molecules. Furthermore, a large number of CDMO collaborations, expansions, mergers & acquisitions, and other strategic initiatives undertaken by market players operating in the country are anticipated to boost the market. For instance, In March 2023, Remedium Bio, a U.S.-based biotechnology company, entered into a collaboration agreement with Exothera, a Belgium-based CDMO, to scale up the production of Remedium's lead gene therapy drug candidate, AAV2-FGF18 in the treatment of osteoarthritis. Similarly, in January 2024, Enzene Biosciences, a subsidiary of Alkem Labs announced the manufacturing site in the U.S. Such innovations are anticipated to drive the market.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Healthcare Contract Development and Manufacturing Organization Market Report Highlights

  • Based on services, the contract manufacturing segment dominated the market with a revenue share of 73.50% in 2023 due to increase in the outsourcing of manufacturing services by pharmaceutical and medical device companies.In addition, cost-effectiveness, and the increasing number of CMOs are some of the key factors that are positively affecting the market growth
  • By small molecule contract development sub-segment, the preclinical/segment is expected to register the highest CAGR of 9.53% in the forecast period due to the rising pipeline of novel therapeutics
  • North America dominated the healthcare contract development and manufacturing organization industry with the largest revenue share of 40.91%in 2023. High shares of the region are majorly due to the presence of a large number of actively functioning CROs and CMOs in the region, especially across the U.S.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Research Methodology And Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Services
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective-1
1.4.2. Objective-2
1.4.3. Objective-3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Healthcare CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Product Pipeline Analysis, by Service
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing Outsourcing Services By Pharmaceutical Companies
3.3.1.2. Rising Investment In R&D
3.3.1.3. Growing Pharmaceutical Industry
3.3.1.4. Increasing Demand For One-Stop-Shop CDMOs
3.3.2. Market Restraint Analysis
3.3.2.1. Compliance Issues While Outsourcing
3.3.2.2. Changing Scenarios In Developing Countries
3.3.2.3. Regulatory And Legal Compliance
3.4. Healthcare CDMO Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier Power
3.4.1.2. Buyer Power
3.4.1.3. Substitution Threat
3.4.1.4. Threat Of New Entrant
3.4.1.5. Competitive Rivalry
3.4.2. PESTEL Analysis
3.4.3. COVID-19 Impact Analysis
3.4.4. Major Deals & Strategic Alliances Analysis
3.4.4.1. Mergers & Acquisitions
3.4.4.2. Geographic Expansions
3.4.4.3. Partnerships
3.4.4.4. Launch
3.4.4.5. Collaborations
Chapter 4. Healthcare CDMO Market: Services Estimates & Trend Analysis
4.1. Healthcare CDMO Market, By Services: Segment Dashboard
4.2. Healthcare CDMO Market, By Services: Movement Analysis
4.3. Healthcare CDMO Market Estimates & Forecasts, By Services, 2018 - 2030
4.3.1. Contract Development
4.3.1.1. Contract Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2. Small Molecule
4.3.1.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.2. Preclinical
4.3.1.2.2.1. Preclinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.2.2. Bioanalysis and DMPK studies
4.3.1.2.2.2.1. Bioanalysis and DMPK studies Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.2.3. Toxicology Testing
4.3.1.2.2.3.1. Toxicology Testing Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.2.4. Other Preclinical Services
4.3.1.2.2.4.1. Other Preclinical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.3. Clinical
4.3.1.2.3.1. Clinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.3.2. Phase I
4.3.1.2.3.2.1. Phase I Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.3.3. Phase II
4.3.1.2.3.3.1. Phase II Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.3.4. Phase III
4.3.1.2.3.4.1. Phase III Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.3.5. Phase IV
4.3.1.2.3.5.1. Phase IV Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.4. Laboratory Services
4.3.1.2.4.1. Laboratory Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.4.2. Bioanalytical Services
4.3.1.2.4.2.1. Bioanalytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.2.4.3. Analytical Services
4.3.1.2.4.3.1. Analytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3. Large Molecule
4.3.1.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.2. Cell line development
4.3.1.3.2.1. Cell line development Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3. Process Development
4.3.1.3.3.1. Process Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.2. Upstream
4.3.1.3.3.2.1. Upstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.2.2. Microbial
4.3.1.3.3.2.2.1. Microbial Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.2.3. Mammalian
4.3.1.3.3.2.3.1. Mammalian Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.2.4. Others
4.3.1.3.3.2.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.3. Downstream
4.3.1.3.3.3.1. Downstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.3.2. MABs
4.3.1.3.3.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.3.3. Recombinant Proteins
4.3.1.3.3.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.1.3.3.3.4. Others
4.3.1.3.3.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2. Contract Manufacturing
4.3.2.1. Contract Manufacturing Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.2. Small Molecule
4.3.2.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.3. Large Molecule
4.3.2.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.3.2. MABs
4.3.2.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.3.3. Recombinant Proteins
4.3.2.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.3.4. Others
4.3.2.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.4. High Potency API
4.3.2.4.1. High Potency API Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.5. Finished Dose Formulations
4.3.2.5.1. Finished Dose Formulations Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.5.2. Solid Dose Formulation
4.3.2.5.2.1. Solid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.5.3. Liquid Dose Formulation
4.3.2.5.3.1. Liquid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.5.4. Injectable Dose Formulation
4.3.2.5.4.1. Injectable Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.6. Medical Device
4.3.2.6.1. Medical Device Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.6.2. Class I
4.3.2.6.2.1. Class I Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.6.3. Class II
4.3.2.6.3.1. Class II Healthcare CDMO Market, 2018 to 2030 (USD Million)
4.3.2.6.4. Class III
4.3.2.6.4.1. Class III Healthcare CDMO Market, 2018 to 2030 (USD Million)
Chapter 5. Healthcare CDMO Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2022 & 2030
5.2. Regional Market Dashboard
5.3. Global Regional Market Snapshot
5.4. North America
5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
5.4.2. U.S.
5.4.2.1. Key Country Dynamics
5.4.2.2. Competitive Scenario
5.4.2.3. Regulatory Framework
5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
5.4.3. Canada
5.4.3.1. Key Country Dynamics
5.4.3.2. Competitive Scenario
5.4.3.3. Regulatory Framework
5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
5.5. Europe
5.5.1. UK
5.5.1.1. Key Country Dynamics
5.5.1.2. Competitive Scenario
5.5.1.3. Regulatory Framework
5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
5.5.2. Germany
5.5.2.1. Key Country Dynamics
5.5.2.2. Competitive Scenario
5.5.2.3. Regulatory Framework
5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
5.5.3. France
5.5.3.1. Key Country Dynamics
5.5.3.2. Competitive Scenario
5.5.3.3. Regulatory Framework
5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
5.5.4. Italy
5.5.4.1. Key Country Dynamics
5.5.4.2. Competitive Scenario
5.5.4.3. Regulatory Framework
5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
5.5.5. Spain
5.5.5.1. Key Country Dynamics
5.5.5.2. Competitive Scenario
5.5.5.3. Regulatory Framework
5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
5.5.6. Denmark
5.5.6.1. Key Country Dynamics
5.5.6.2. Competitive Scenario
5.5.6.3. Regulatory Framework
5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
5.5.7. Sweden
5.5.7.1. Key Country Dynamics
5.5.7.2. Competitive Scenario
5.5.7.3. Regulatory Framework
5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
5.5.8. Norway
5.5.8.1. Key Country Dynamics
5.5.8.2. Competitive Scenario
5.5.8.3. Regulatory Framework
5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
5.5.9. Netherlands
5.5.9.1. Key Country Dynamics
5.5.9.2. Competitive Scenario
5.5.9.3. Regulatory Framework
5.5.9.4. Netherlands Market Estimates and Forecasts, 2018 - 2030
5.5.10. Belgium
5.5.10.1. Key Country Dynamics
5.5.10.2. Competitive Scenario
5.5.10.3. Regulatory Framework
5.5.10.4. Belgium Market Estimates and Forecasts, 2018 - 2030
5.6. Asia Pacific
5.6.1. Japan
5.6.1.1. Key Country Dynamics
5.6.1.2. Competitive Scenario
5.6.1.3. Regulatory Framework
5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
5.6.2. India
5.6.2.1. Key Country Dynamics
5.6.2.2. Competitive Scenario
5.6.2.3. Regulatory Framework
5.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
5.6.3. China
5.6.3.1. Key Country Dynamics
5.6.3.2. Competitive Scenario
5.6.3.3. Regulatory Framework
5.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
5.6.4. South Korea
5.6.4.1. Key Country Dynamics
5.6.4.2. Competitive Scenario
5.6.4.3. Regulatory Framework
5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
5.6.5. Australia
5.6.5.1. Key Country Dynamics
5.6.5.2. Competitive Scenario
5.6.5.3. Regulatory Framework
5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
5.6.6. Thailand
5.6.6.1. Key Country Dynamics
5.6.6.2. Competitive Scenario
5.6.6.3. Regulatory Framework
5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
5.6.7. Malaysia
5.6.7.1. Key Country Dynamics
5.6.7.2. Competitive Scenario
5.6.7.3. Regulatory Framework
5.6.7.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
5.6.8. New Zealand
5.6.8.1. Key Country Dynamics
5.6.8.2. Competitive Scenario
5.6.8.3. Regulatory Framework
5.6.8.4. New Zealand Market Estimates and Forecasts, 2018 - 2030
5.6.9. Singapore
5.6.9.1. Key Country Dynamics
5.6.9.2. Competitive Scenario
5.6.9.3. Regulatory Framework
5.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030
5.6.10. Philippines
5.6.10.1. Key Country Dynamics
5.6.10.2. Competitive Scenario
5.6.10.3. Regulatory Framework
5.6.10.4. Philippines Market Estimates and Forecasts, 2018 - 2030
5.7. Latin America
5.7.1. Brazil
5.7.1.1. Key Country Dynamics
5.7.1.2. Competitive Scenario
5.7.1.3. Regulatory Framework
5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
5.7.2. Mexico
5.7.2.1. Key Country Dynamics
5.7.2.2. Competitive Scenario
5.7.2.3. Regulatory Framework
5.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
5.7.3. Argentina
5.7.3.1. Key Country Dynamics
5.7.3.2. Competitive Scenario
5.7.3.3. Regulatory Framework
5.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
5.7.4. Colombia
5.7.4.1. Key Country Dynamics
5.7.4.2. Competitive Scenario
5.7.4.3. Regulatory Framework
5.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
5.7.5. Chile
5.7.5.1. Key Country Dynamics
5.7.5.2. Competitive Scenario
5.7.5.3. Regulatory Framework
5.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
5.8. MEA
5.8.1. South Africa
5.8.1.1. Key Country Dynamics
5.8.1.2. Competitive Scenario
5.8.1.3. Regulatory Framework
5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
5.8.2. Saudi Arabia
5.8.2.1. Key Country Dynamics
5.8.2.2. Competitive Scenario
5.8.2.3. Regulatory Framework
5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
5.8.3. UAE
5.8.3.1. Key Country Dynamics
5.8.3.2. Competitive Scenario
5.8.3.3. Regulatory Framework
5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
5.8.4. Kuwait
5.8.4.1. Key Country Dynamics
5.8.4.2. Competitive Scenario
5.8.4.3. Regulatory Framework
5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
5.8.5. Israel
5.8.5.1. Key Country Dynamics
5.8.5.2. Competitive Scenario
5.8.5.3. Regulatory Framework
5.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.1.1. Innovators
6.1.2. Market Leaders
6.1.3. Emerging Players
6.1.4. Company Market Share Analysis, 2022
6.2. Company Profiles
6.2.1. Catalent Inc.
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Service Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. Lonza
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Service Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Recipharm AB
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Service Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Siegfried Holding AG
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Service Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Thermo Fisher Scientific, Inc
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Service Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Labcorp Drug Development
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Service Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Jabil Inc
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Service Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Syngene International Limited
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Service Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. IQVIA Inc.
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Service Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. Almac Group
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Service Benchmarking
6.2.10.4. Strategic Initiatives
6.2.11. Ajinomoto Bio-Pharma
6.2.11.1. Company Overview
6.2.11.2. Financial Performance
6.2.11.3. Service Benchmarking
6.2.11.4. Strategic Initiatives
6.2.12. Adare Pharma Solutions
6.2.12.1. Company Overview
6.2.12.2. Financial Performance
6.2.12.3. Service Benchmarking
6.2.12.4. Strategic Initiatives
6.2.13. Alcami Corporation
6.2.13.1. Company Overview
6.2.13.2. Financial Performance
6.2.13.3. Service Benchmarking
6.2.13.4. Strategic Initiatives
6.2.14. Vetter Pharma International
6.2.14.1. Company Overview
6.2.14.2. Financial Performance
6.2.14.3. Service Benchmarking
6.2.14.4. Strategic Initiatives
Chapter 7. KoL Commentary/Recommendations
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Healthcare CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION Market, By Region 2018 - 2030 (USD Million)
Table 4 Global Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 5 North America Healthcare Contract Development and Manufacturing Organization Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 7 U.S. Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 8 Canada Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 9 Europe Healthcare Contract Development and Manufacturing Organization Market, By Country, 2018 - 2030 (USD Million)
Table 10 Europe Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 11 U.K. Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 12 Germany Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 13 France Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 14 Italy Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 15 Spain Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 16 Netherlands Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 17 Belgium Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 18 Denmark Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 19 Norway Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 20 Sweden Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 21 Asia Pacific Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 22 China Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 23 Japan Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 24 India Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 25 Australia Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 26 South Korea Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 27 Malaysia Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 28 New Zealand Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 29 Singapore Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 30 Philippines Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 31 Thailand Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 32 Latin America Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 33 Brazil Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 34 Mexico Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 35 Argentina Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 36 Colombia Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 37 Chile Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 38 Middle East & Africa Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 39 South Africa Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 40 Saudi Arabia Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 41 UAE Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 42 Israel Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
Table 43 Kuwait Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Healthcare contract development and manufacturing organization market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Data analysis models
Fig. 5 Market formulation and validation
Fig. 6 Data validating & publishing
Fig. 7 Commodity flow analysis
Fig. 8 Market snapshot
Fig. 9 Segment snapshot
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market outlook, 2023 (USD Billion)
Fig. 13 Ancillary market outlook, 2023 (USD Billion)
Fig. 14 Healthcare contract development and manufacturing organization market dynamics
Fig. 15 Porter’s five forces analysis
Fig. 16 PESTEL analysis
Fig. 17 Healthcare contract development and manufacturing organization market : Services outlook and key takeaways
Fig. 18 Healthcare contract development and manufacturing organization market : Services movement analysis
Fig. 19 Contract Development market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Small Molecule market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Preclinical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Bioanalysis and DMPK Studies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Toxicology Testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Other Preclinical Services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Clinical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Laboratory Services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Bioanalytical Services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Analytical Services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Large Molecule market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Cell Line development market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Process Development market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Upstream market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Microbial market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Mammalian market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Downstream market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 MABs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Recombinant Proteins market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Contract Manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Small Molecule market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Large Molecule market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 MABs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Recombinant Proteins market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 High Potency API market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Finished Dose Formulations market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Solid Dose Formulation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Liquid Dose Formulation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Injectable Dose Formulation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Medical Devices market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Class I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Class II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Class III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Regional market: Key takeaways
Fig. 61 Regional outlook, 2023 & 2030
Fig. 62 Regional outlook, 2023 & 2030
Fig. 63 North America Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 U.S. Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Canada Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Germany Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 UK Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 France Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Italy Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Spain Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Key country dynamics
Fig. 79 Netherlands Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 Belgium Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Denmark Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Norway Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Sweden Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 China Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 India Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Japan Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Australia Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 South Korea Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 Malaysia Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Key country dynamics
Fig. 101 New Zealand Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Key country dynamics
Fig. 103 Singapore Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 104 Key country dynamics
Fig. 105 Philippines Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Key country dynamics
Fig. 107 Thailand Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 Key country dynamics
Fig. 109 Brazil Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Key country dynamics
Fig. 111 Mexico Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Key country dynamics
Fig. 113 Argentina Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 114 Key country dynamics
Fig. 115 Colombia Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Key country dynamics
Fig. 117 Chile Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 118 Key country dynamics
Fig. 119 South Africa Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 120 Key country dynamics
Fig. 121 Saudi Arabia Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 122 Key country dynamics
Fig. 123 UAE Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 124 Key country dynamics
Fig. 125 Israel Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 126 Key country dynamics
Fig. 127 Kuwait Healthcare contract development and manufacturing organization market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • Catalent Inc.
  • Lonza
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific, Inc
  • Labcorp Drug Development
  • Jabil Inc
  • Syngene International Limited
  • IQVIA Inc.
  • Almac Group
  • Ajinomoto Bio-Pharma
  • Adare Pharma Solutions
  • Alcami Corporation
  • Vetter Pharma International

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages145
PublishedJuly 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 249.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 471 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report by Product Type (Tablets, Capsules, Powders, Granules), Mechanism, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report by Product Type (Tablets, Capsules, Powders, Granules), Mechanism, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 193 Pages
  • Global
From
Semi-solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Topical, Transdermal, Oral), By Product (Creams, Gels), By End Use, By Company Size, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Semi-solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Topical, Transdermal, Oral), By Product (Creams, Gels), By End Use, By Company Size, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Healthcare Contract Development & Manufacturing Organization Market by Services, End-User - Global Forecast 2025-2030 - Product Image

Healthcare Contract Development & Manufacturing Organization Market by Services, End-User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Biologics Contract Development & Manufacturing Organization Market by Type, Product Type, Disease Indication, Service Type, End-User - Global Forecast 2025-2030 - Product Image

Biologics Contract Development & Manufacturing Organization Market by Type, Product Type, Disease Indication, Service Type, End-User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report - Product Image

Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From

About the Healthcare CDMO Market

The Healthcare CDMO market is a subset of the larger Healthcare Services industry. It is comprised of Contract Development and Manufacturing Organizations (CDMOs) that provide services to the pharmaceutical and biotechnology industries. These services include drug development, clinical trial management, manufacturing, packaging, and distribution. CDMOs are responsible for the development and production of drugs, biologics, and medical devices, as well as the delivery of these products to the end user. CDMOs are an integral part of the healthcare industry, providing a range of services that enable the development and delivery of safe and effective treatments. They are also responsible for ensuring that products meet regulatory requirements and are of the highest quality. Some of the companies in the Healthcare CDMO market include Patheon, Catalent, Recipharm, Aenova, and Vetter. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.